New hope for tough pancreatic cancer: trial tests drug to boost chemo and prevent clots
NCT ID NCT07214298
Summary
This study is testing whether adding a new drug called pegcetacoplan to a standard chemotherapy regimen (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan aims to help the immune system fight the cancer and may also reduce the risk of dangerous blood clots, which are common in this disease. The trial will enroll about 35 adults who have not had prior chemotherapy for their metastatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.